🏢 官网IRSNDXCodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:01:53 +1m53s·⚡ 决策 07-28 19:03:30 +1m37s·91.1 天前
Syndax宣布将于8月4日披露二季度财报并召开电话会
本次只是财报披露和电话会排期通知，没有收入、利润、指引、临床、监管或商业化新增信息。
📄 原文SNDX↗ 原文
NEW YORK , July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutica…
不做 Syndax Pharmaceuticals（SNDX.US）
仅为二季度财报和电话会排期通知，没有业绩数据、指引变化、临床进展或监管事件，当前不形成同向可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是财报披露和电话会排期通知，没有收入、利润、指引、临床、监管或商业化新增信息。
主要风险
- 真正可交易的信息需等2026年8月4日二季度财报和业务更新披露后再判断。
原文全文
展开原文 · 1,855 字
NEW YORK
,
July 28, 2026
(GLOBE NEWSWIRE) --
Syndax Pharmaceuticals
(Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on
Tuesday, August 4, 2026
.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at
4:30 p.m. ET
on
Tuesday, August 4, 2026
.
The live audio webcast and accompanying slides may be accessed through the
Events & Presentations page
in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax2Q26
Domestic Dial
-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast:
https://sndx-2q26.open-exchange.net/
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at
www.syndax.com
approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj
®
(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit
www.syndax.com
or follow the Company on
X
and
LinkedIn
.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
,
July 28, 2026
(GLOBE NEWSWIRE) --
Syndax Pharmaceuticals
(Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on
Tuesday, August 4, 2026
.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at
4:30 p.m. ET
on
Tuesday, August 4, 2026
.
The live audio webcast and accompanying slides may be accessed through the
Events & Presentations page
in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax2Q26
Domestic Dial
-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast:
https://sndx-2q26.open-exchange.net/
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at
www.syndax.com
approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj
®
(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit
www.syndax.com
or follow the Company on
X
and
.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。